Saliva amyloid proposed as Alzheimer disease biomarker


A pilot study of potential Alzheimer disease biomarkers has proposed that highly sensitive ELISA testing of amyloid levels in saliva may help to distinguish AD from other types of dementia at an early stage of the disease process (Bermejo-Pareja et al. BMC Neurol 2010; 10: 108).

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page